Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

Published:2006-07-19 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Appleton Sarah¹,Poole Phillippa²,Smith Brian J³,Veale Antony⁴,Lasserson Toby J⁵,Chan Matthew Ming Ki⁶,Cates Christopher J⁷

Affiliation:

1. The Queen Elizabeth Hospital; Deptartment of Medicine; Woodville Road Adelaide South Australia Australia 5011

2. University of Auckland; Department of Medicine; Private Bag 92019 Auckland New Zealand

3. The Queen Elizabeth Hospital; Department of Medicine, University of Adelaide; Adelaide South Australia Australia 5011

4. The Queen Elizabeth Hospital; Respiratory Medicine; Adelaide South Australia Australia

5. The Cochrane Collaboration; Cochrane Editorial Unit; 13 Cavendish Square London UK W1G 0AN

6. The Crown Princess Mary Cancer Centre Westmead, Westmead Hospital; Medical Oncology; Westmead New South Wales Australia 2145

7. St George's, University of London; Population Health Sciences and Education; Cranmer Terrace London UK SW17 0RE

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD001104.pub2/fullpdf

Reference144 articles.

1. 408D03 A multi-center, randomized, double-blind, parallel-group, comparison of salmeterol xinafoate inhalation Rotadisk versus placebo in subjects with chronic obstructive pulmonary disease treated with current medications GlaxoSmithKline Clinical Trial Register (http:ctr.gsk.co.uk) 2005

2. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD);Boyd;European Respiratory Journal,1997

3. Quality of life changes in COPD patients treated with salmeterol;Jones;American Journal of Respiratory & Critical Care Medicine,1997

4. SLGT28 A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of inhaled salmeterol xinafoate 50µg bd and inhaled salmeterol xinafoate 100µg bd with placebo, all administered via the metered-dose inhaler, in the treatment of patients with chronic obstructive pulmonary disease GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005

5. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial;Calverley;The Lancet,2003

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?;European Journal of Clinical Pharmacology;2024-02-23

2. Risk and distribution of chronic obstructive pulmonary disease–related hospitalizations among primary care patients;Canadian Family Physician;2023-06

3. Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease;Journal of Personalized Medicine;2022-05-31

4. Effects of cigarette smoke exposure on pulmonary physiology, muscle strength and exercise capacity in a retrospective cohort with 30,000 subjects;PLOS ONE;2021-06-24

5. Characteristics and outcomes of diabetic patients with acute exacerbation of COPD;Journal of Diabetes & Metabolic Disorders;2021-04-23